-+ 0.00%
-+ 0.00%
-+ 0.00%

THE U.S. FDA GRANTS ORPHAN DRUG DESIGNATION FOR LUNDBECK'S INVESTIGATIONAL ANTI-ACTH MONOCLONAL ANTIBODY ASEDEBART FOR TREATMENT OF ENDOGENOUS CUSHING'S SYNDROME

Reuters·09/11/2026 08:22:15

Please log in to view news